Cancer vaccines: an update.
This review summarizes the most recent findings and the future directions in designing cancer vaccines. The newest tumor-associated antigens and the most promising approaches to cancer vaccine development are discussed. We categorized them as follows: peptide vaccines, recombinant viral vaccines, DNA vaccines, dendritic cell-based immunotherapy, and the use of heat shock proteins and adjuvants. We focus on their advantages and disadvantages in addition to clinical potential.
Hipp
J D
JD
Cancer Center, University of California-San Diego, La Jolla, CA 92093-0060, USA.
Hipp
J A
JA
Lyday
B W
BW
Minev
B R
BR
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000818:Animals; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use; D003713:Dendritic Cells / Q000276:immunology; D006360:Heat-Shock Proteins / Q000276:immunology / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy; D019444:Vaccines, DNA / Q000276:immunology / Q000627:therapeutic use; D022223:Vaccines, Subunit / Q000276:immunology / Q000627:therapeutic use; D014614:Vaccines, Synthetic / Q000276:immunology / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D019496:Cancer Vaccines; D006360:Heat-Shock Proteins; D019444:Vaccines, DNA; D022223:Vaccines, Subunit; D014614:Vaccines, Synthetic